| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 1
| Issue : 1 | Page : 27-30 |
|
|
Glycation: A connecting link between diabetes and COVID-19
Sneha B Bansode1, Rakesh S Joshi2, Ashok P Giri2, Mahesh J Kulkarni2
1 Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, Maharashtra, India
2 Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, Maharashtra; Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India
Correspondence Address:
Mahesh J Kulkarni
Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune - 411 008, Maharashtra
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/cdrp.cdrp_8_21
|
|
|
Diabetes is considered as a risk factor for the severity of coronavirus disease 2019 (COVID-19). The mortality rate of COVID-19 was found to be high among patients with diabetes. The exact molecular mechanism involved in diabetes-associated COVID-19 severity is not established. In this review, we discuss the exacerbated formation of advanced glycation end products (AGEs), AGE-receptor for AGE (RAGE) signaling induced spike in inflammatory cytokines, and the role of metformin, an antidiabetic drug with glycation inhibition property. The commonality between these two diseases is exacerbated immune response. AGEs interact with RAGE, leading to oxidative stress, activation of the pro-inflammatory pathway, and production of inflammatory cytokines, which may aberrantly activate the immune response. Based on these pieces of evidence, we propose a role for glycation in the pathogenesis of COVID-19 severity.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
